Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.
US veterans with chronic cardiovascular conditions experiencing homelessness and unstable housing have lower outpatient care utilization.
The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback